These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 25864703)

  • 1. Serum infliximab concentrations and disease activity: a descriptive study of patients with psoriasis.
    Dannepond C; Ternant D; Maruani A; Machet L; Paintaud G; Samimi M
    Br J Dermatol; 2016 Jan; 174(1):198-200. PubMed ID: 25864703
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum infliximab concentrations in psoriatic patients treated with infliximab: a systematic review.
    Dannepond C; Maruani A; Machet L; Ternant D; Paintaud G; Samimi M
    Acta Derm Venereol; 2015 Apr; 95(4):401-6. PubMed ID: 25270995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: Results of the SPREAD study.
    Torii H; Nakano M; Yano T; Kondo K; Nakagawa H;
    J Dermatol; 2017 May; 44(5):552-559. PubMed ID: 27882586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy of infliximab and ciclosporin in the treatment of recalcitrant psoriasis: a case series.
    Martinez-Mera C; Camarero-Mulas C; Sanz-Sánchez T; Daudén E
    Br J Dermatol; 2017 Mar; 176(3):803-805. PubMed ID: 27943238
    [No Abstract]   [Full Text] [Related]  

  • 5. To pretreat or not to pretreat? The experience of three Italian Psoriasis centres on the use of premedication with Infliximab.
    Bardazzi F; Savoia F; Di Lernia V; Tengattini V; Balestri R; Patrizi A; Magnano M
    J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):e55-e57. PubMed ID: 26337536
    [No Abstract]   [Full Text] [Related]  

  • 6. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.
    Hroch M; Chladek J; Simkova M; Vaneckova J; Grim J; Martinkova J
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):19-24. PubMed ID: 18031504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dramatic response to a single dose of infliximab in a patient with prolonged pustular psoriasis derived from inverse psoriasis.
    Li M; Dai W; Yan W; Liu Y; Wang L; Li W
    Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28419647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term durability and dose escalation patterns in infliximab therapy for psoriasis.
    Luber AJ; Tsui CL; Heinecke GM; Lebwohl MG; Levitt JO
    J Am Acad Dermatol; 2014 Mar; 70(3):525-32. PubMed ID: 24388425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
    Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
    Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful use of infliximab as first line treatment for severe childhood generalized pustular psoriasis.
    Tsang V; Dvorakova V; Enright F; Murphy M; Gleeson C
    J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):e117-e119. PubMed ID: 26403378
    [No Abstract]   [Full Text] [Related]  

  • 11. Efalizumab rebound response to a sequential therapy of infliximab followed by efalizumab.
    Brunasso AM; Delfino C; Massone C
    Dermatology; 2009; 218(1):73-4. PubMed ID: 18841002
    [No Abstract]   [Full Text] [Related]  

  • 12. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study.
    Gottlieb AB; Kalb RE; Blauvelt A; Heffernan MP; Sofen HL; Ferris LK; Kerdel FA; Calabro S; Wang J; Kerkmann U; Chevrier M
    J Am Acad Dermatol; 2012 Oct; 67(4):642-50. PubMed ID: 22153792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis.
    Bito T; Nishikawa R; Hatakeyama M; Kikusawa A; Kanki H; Nagai H; Sarayama Y; Ikeda T; Yoshizaki H; Seto H; Adachi A; Horikawa T; Oka M; Nishigori C
    Br J Dermatol; 2014 Apr; 170(4):922-9. PubMed ID: 24329764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential therapy in plaque psoriasis using the " Hit and Run " approach: infliximab followed by efalizumab.
    Penz S; Pelletier F; Riou-Gotta MO; Puzenat E; Levang J; Mermet I; Humbert P; Aubin F
    Int J Dermatol; 2012 Feb; 51(2):236-7. PubMed ID: 22250639
    [No Abstract]   [Full Text] [Related]  

  • 15. The value of monitoring ciclosporin concentration 2 hours post-dose (C2) in dermatology: a prospective cohort study.
    Chew AL; Bashir SJ; Johnston A; Barker JN; Smith CH
    J Dermatolog Treat; 2011 Apr; 22(2):79-85. PubMed ID: 20673153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade.
    Winterfield L; Menter A
    Dermatol Clin; 2004 Oct; 22(4):437-47, ix. PubMed ID: 15450339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal biologic dosing in management of obese patients with psoriasis.
    Neema S; Pathania V; Pudasaini N; Subramaniyan R
    Indian J Dermatol Venereol Leprol; 2021; 87(3):424-426. PubMed ID: 33666055
    [No Abstract]   [Full Text] [Related]  

  • 18. Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review.
    Kamili QU; Miner A; Hapa A; Menter A
    J Drugs Dermatol; 2011 May; 10(5):539-44. PubMed ID: 21533302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis due to EBV-reactivation under infliximab in a psoriasis patient.
    Sondermann W; Baba HA; Körber A
    Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28771953
    [No Abstract]   [Full Text] [Related]  

  • 20. Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre.
    Wee JS; Petrof G; Jackson K; Barker JN; Smith CH
    Br J Dermatol; 2012 Aug; 167(2):411-6. PubMed ID: 22404545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.